Authors
Latest:
Dr. Cascone on Combination Checkpoint Blockade for Early-Stage Non–Small-Cell Lung CancerCancer Network spoke with Tina Cascone, MD, of MD Anderson Cancer Center, at ASCO 2019 about combination checkpoint blockade in the pre-surgical setting for early-stage NSCLC.
Latest:
Dr. Chiara Cremolini on the Updated Results of the TRIBE2 Study for Unresectable Colorectal CancerCancer Network spoke with Chiara Cremolini, MD, about the updated results of the phase III randomized strategy study TRIBE2, which looked at the first- and second-line treatment of unresectable metastatic colorectal cancer.
Latest:
Dr. Hala Borno on Addressing Disparities in Access to Prostate Cancer CareCancer Network spoke with Hala Borno, MD, of the University of California, San Francisco, about addressing the disparities in access to clinical trials and treatments for patients with prostate cancer.
Latest:
Incidence of Non-Melanoma Skin Cancer Tallies Biggest Change From 2016 to 2017The Global Burden of Disease 2017 study found non-melanoma skin cancer to be the biggest increase in incidence worldwide.
Latest:
Dr. Arbour on the Latest Data for Checkpoint Inhibitors for Lung Cancer in 2019Cancer Network spoke with Kathryn Cecilia Arbour, MD, of Memorial Sloan-Kettering Cancer Center, about the most recent research on checkpoint inhibitors in oncology.
Latest:
Dr. Yoland Catherine Antill on Results of the PHAEDRA TrialCancer Network spoke with Yoland Catherine Antill, MD, of Cabrini Health, about the phase II PHAEDRA trial, which tested the activity of durvalumab in advanced endometrial cancer according to mismatch repair status.
Latest:
Dr. Jason Westin on Combination Targeted Therapy Prior to Chemotherapy for DLBCLCancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.
Latest:
Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma PatientsCancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.
Latest:
Hussein Tawbi, MD, PhD, Discusses Results From the COMBI-AD TrialData from the COMBI-AD Trial evaluating dabrafenib and trametinib to treat melanoma was analyzed by Hussein Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center.
Latest:
Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in RemissionCancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.
Latest:
Dr. Thomas Gajewski on Analyzing the Tumor Microenvironment to Guide Immunotherapy in MelanomaCancer Network spoke with Thomas Gajewski, MD, PhD, of the University of Chicago Medical Center, about analyzing the tumor microenvironment to guide immunotherapy in melanoma.
Latest:
Dr. Janice M. Mehnert on Immunotherapy vs BRAF/MEK Inhibitors in the Adjuvant Setting for MelanomaCancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma.
Latest:
Dr. Meyers on Low-Dose Tamoxifen vs Placebo After Surgery for DCIS Breast CancerCancer Network spoke with Marleen Meyers, MD, about evidence on low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ.
Latest:
Dr. Adi Diab on Baseline Tumor Immune Signatures and Therapy Response in Solid TumorsCancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.
Latest:
Fergus Couch, PhD, on the CARRIERS Studies in Breast CancerFergus Couch, PhD, from the Mayo Clinic, discusses with CancerNetwork about the new research with the CARRIERS study for African American patients with breast cancer.
Latest:
Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?This review summarizes the major clinical trials that led to the approval of antiangiogenic drugs for ovarian cancer and gives a brief view into novel combinations of bevacizumab with other targeted therapies in an attempt to enhance the efficacy of bevacizumab.
Latest:
Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?This review summarizes the major clinical trials that led to the approval of antiangiogenic drugs for ovarian cancer and gives a brief view into novel combinations of bevacizumab with other targeted therapies in an attempt to enhance the efficacy of bevacizumab.
Latest:
Evolution of Lung Cancer Screening ManagementThroughout the last half of the 20th century, despite enormous research efforts, lung cancer remained the most feared as well as lethal cancer across the world. Efforts to update screening management are attempting to change that.
Latest:
Evolution of Lung Cancer Screening ManagementThroughout the last half of the 20th century, despite enormous research efforts, lung cancer remained the most feared as well as lethal cancer across the world. Efforts to update screening management are attempting to change that.
Latest:
Evolution of Lung Cancer Screening ManagementThroughout the last half of the 20th century, despite enormous research efforts, lung cancer remained the most feared as well as lethal cancer across the world. Efforts to update screening management are attempting to change that.
Latest:
Evolution of Lung Cancer Screening ManagementThroughout the last half of the 20th century, despite enormous research efforts, lung cancer remained the most feared as well as lethal cancer across the world. Efforts to update screening management are attempting to change that.
Latest:
Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid LeukemiaThis article summarizes available data for the use of CYP3A4 inhibitors with midostaurin for acute myeloid leukemia.
Latest:
Multiple Primary Tumors Over a LifetimeThe risk of multiple primary cancers is increasing due to increasing numbers of survivors, long-term side effects of chemotherapy and/or radiation therapy, increased diagnostic sensitivity, and persisting effects of genetic and behavioral risk factors.
Latest:
Diffuse Hepatic Infiltration by Metastatic MelanomaMelanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.
Latest:
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular CarcinomaA thought-provoking installment of Clinical Quandaries is presented by Alejandro Gabutti, MD; and Tommaso Cascella, MD, of a 36-year-old patient with hepatitis C virus-related cirrhosis and a subsequent diagnosis of hepatocellular carcinoma.
Latest:
Diffuse Hepatic Infiltration by Metastatic MelanomaMelanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.
Latest:
Dr. Kelly Hunt on the Role of Surgery in Metastatic Breast CancerCancer Network spoke with Kelly Hunt, MD, professor and chair of the department of breast surgical oncology at the MD Anderson Cancer Center in Houston, about the role of surgery in metastatic breast cancer.
Latest:
Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon CancerThis case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
Latest:
Management of Steroid-Refractory Immune-Related Adverse EventsThe increasing utilization of these immune checkpoint inhibitors has presented new of immune-related adverse events that have proven to be extremely challenging to manage.
